FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578040199> ?p ?o ?g. }

• W2578040199 endingPage "3430" @default.
• W2578040199 startingPage "3430" @default.
• W2578040199 abstract "Abstract Introduction: Citron rho-interacting serine/threonine kinase (CIT) is a serine/threonine kinase which is a key component of the midbody and is essential for cytokinesis. CIT localizes to the central spindle and midbody and functions to promote efficient cytokinesis. CIT knockdown may disrupt cytokinesis and therefore cell growth. CIT has been reported to be upregulated and important for growth of several cancers. However, the significance of CIT has not been investigated in the field of multiple myeloma (MM). We therefore dissected the role of CIT in MM growth in vitro and in vivo. Materials and methods: CIT gene expression in MM cells was compared to normal plasma cells using public-available gene expression profile (GEP) data set (GSE6477). Kaplan-Meier curve for MM patient survival between high and low CIT expressing patients were examined by using the GEP data set (GSE4581). Protein expression of CIT in MM cells was confirmed by proteomic analysis and immunohistochemistry. Knockdown of CIT was performed in MM cell lines MM1s and OPM2 using lentiviral shRNAs. CIT knockdown was confirmed by reduced CIT mRNA in comparison to a scrambled control. Differences in cell proliferation and cell cycle between CIT knockdown cells and scramble control were analyzed by using thymidine uptake and PI staining, respectively. Cytokinesis failure was analyzed by immunofluorescence using alpha-tubulin antibody and DAPI. shCIT OPM2 (n=7) and the scrambled control cells (n=8) were injected subcutaneously into SCID-Bg mice (5x106 cells/mouse) and were followed for tumor development and survival. Results: CIT expression was significantly higher in MM patients’ plasma cells compared to healthy donors in GEP (p=0.02), proteomic analysis and immunohistochemistry. Also CIT expression was higher in relapsed patients compared to newly diagnosed patients by GEP. MM patients with high CIT expression had significantly worse overall survival compared to low CIT expressing patients (p=0.04). CIT knockdown MM cell lines showed reduced cell proliferation and G2 cell cycle arrest by thymidine uptake and PI staining compared to the scrambled control. Significantly, large amount of multinucleated cells, which indicates cytokinesis failure, were observed in the CIT knockdown cells compared to scrambled control. Reduced tumor growth (p<0.001) and prolonged survival (p<0.001) was observed in CIT knockdown MM cell line injected mice. Conclusions: shRNA knockdown of CIT in MM cells induces G2 arrest leading to cytokinesis failure in vitro with reduced cell proliferation in vivo. Since MM cells have significantly higher expression of CIT compared to normal plasma cells, CIT represents a novel therapeutic target for MM. Studies are ongoing to develop drugs to target CIT for MM treatment. Disclosures Anderson: Celgene: Consultancy; Sanofi-Aventis: Consultancy; Onyx: Consultancy; Acetylon: Scientific Founder, Scientific Founder Other; Oncoprep: Scientific Founder Other; Gilead Sciences: Consultancy. Ghobrial:Onyx: Advisory board Other; BMS: Advisory board, Advisory board Other, Research Funding; Noxxon: Research Funding; Sanofi: Research Funding." @default.
• W2578040199 created "2017-01-26" @default.
• W2578040199 creator A5004739031 @default.
• W2578040199 creator A5009466687 @default.
• W2578040199 creator A5014353611 @default.
• W2578040199 creator A5022352605 @default.
• W2578040199 creator A5023152679 @default.
• W2578040199 creator A5032464400 @default.
• W2578040199 creator A5036677725 @default.
• W2578040199 creator A5047821211 @default.
• W2578040199 creator A5050778981 @default.
• W2578040199 creator A5059943491 @default.
• W2578040199 creator A5064209980 @default.
• W2578040199 creator A5069865492 @default.
• W2578040199 creator A5072050682 @default.
• W2578040199 creator A5091281426 @default.
• W2578040199 date "2014-12-06" @default.
• W2578040199 modified "2023-10-15" @default.
• W2578040199 title "Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells" @default.
• W2578040199 doi "https://doi.org/10.1182/blood.v124.21.3430.3430" @default.
• W2578040199 hasPublicationYear "2014" @default.
• W2578040199 type Work @default.
• W2578040199 sameAs 2578040199 @default.
• W2578040199 citedByCount "0" @default.
• W2578040199 crossrefType "journal-article" @default.
• W2578040199 hasAuthorship W2578040199A5004739031 @default.
• W2578040199 hasAuthorship W2578040199A5009466687 @default.
• W2578040199 hasAuthorship W2578040199A5014353611 @default.
• W2578040199 hasAuthorship W2578040199A5022352605 @default.
• W2578040199 hasAuthorship W2578040199A5023152679 @default.
• W2578040199 hasAuthorship W2578040199A5032464400 @default.
• W2578040199 hasAuthorship W2578040199A5036677725 @default.
• W2578040199 hasAuthorship W2578040199A5047821211 @default.
• W2578040199 hasAuthorship W2578040199A5050778981 @default.
• W2578040199 hasAuthorship W2578040199A5059943491 @default.
• W2578040199 hasAuthorship W2578040199A5064209980 @default.
• W2578040199 hasAuthorship W2578040199A5069865492 @default.
• W2578040199 hasAuthorship W2578040199A5072050682 @default.
• W2578040199 hasAuthorship W2578040199A5091281426 @default.
• W2578040199 hasConcept C1491633281 @default.
• W2578040199 hasConcept C153911025 @default.
• W2578040199 hasConcept C164265269 @default.
• W2578040199 hasConcept C173396325 @default.
• W2578040199 hasConcept C184235292 @default.
• W2578040199 hasConcept C29537977 @default.
• W2578040199 hasConcept C45472230 @default.
• W2578040199 hasConcept C502942594 @default.
• W2578040199 hasConcept C54355233 @default.
• W2578040199 hasConcept C55493867 @default.
• W2578040199 hasConcept C62112901 @default.
• W2578040199 hasConcept C81885089 @default.
• W2578040199 hasConcept C85813293 @default.
• W2578040199 hasConcept C86803240 @default.
• W2578040199 hasConcept C95444343 @default.
• W2578040199 hasConceptScore W2578040199C1491633281 @default.
• W2578040199 hasConceptScore W2578040199C153911025 @default.
• W2578040199 hasConceptScore W2578040199C164265269 @default.
• W2578040199 hasConceptScore W2578040199C173396325 @default.
• W2578040199 hasConceptScore W2578040199C184235292 @default.
• W2578040199 hasConceptScore W2578040199C29537977 @default.
• W2578040199 hasConceptScore W2578040199C45472230 @default.
• W2578040199 hasConceptScore W2578040199C502942594 @default.
• W2578040199 hasConceptScore W2578040199C54355233 @default.
• W2578040199 hasConceptScore W2578040199C55493867 @default.
• W2578040199 hasConceptScore W2578040199C62112901 @default.
• W2578040199 hasConceptScore W2578040199C81885089 @default.
• W2578040199 hasConceptScore W2578040199C85813293 @default.
• W2578040199 hasConceptScore W2578040199C86803240 @default.
• W2578040199 hasConceptScore W2578040199C95444343 @default.
• W2578040199 hasIssue "21" @default.
• W2578040199 hasLocation W25780401991 @default.
• W2578040199 hasOpenAccess W2578040199 @default.
• W2578040199 hasPrimaryLocation W25780401991 @default.
• W2578040199 hasRelatedWork W1982414245 @default.
• W2578040199 hasRelatedWork W2291638877 @default.
• W2578040199 hasRelatedWork W2532041 @default.
• W2578040199 hasRelatedWork W2533153541 @default.
• W2578040199 hasRelatedWork W2586385055 @default.
• W2578040199 hasRelatedWork W2783802064 @default.
• W2578040199 hasRelatedWork W3043437927 @default.
• W2578040199 hasRelatedWork W3094951633 @default.
• W2578040199 hasRelatedWork W3130220624 @default.
• W2578040199 hasRelatedWork W4294295793 @default.
• W2578040199 hasVolume "124" @default.
• W2578040199 isParatext "false" @default.
• W2578040199 isRetracted "false" @default.
• W2578040199 magId "2578040199" @default.
• W2578040199 workType "article" @default.